skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Nanomedicine in therapeutic warfront against estrogen receptor–positive breast cancer

Aalhate, Mayur ; Mahajan, Srushti ; Singh, Hoshiyar ; Guru, Santosh Kumar ; Singh, Pankaj Kumar

Drug delivery and translational research, 2023-06, Vol.13 (6), p.1621-1653 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível

Citações Citado por
  • Título:
    Nanomedicine in therapeutic warfront against estrogen receptor–positive breast cancer
  • Autor: Aalhate, Mayur ; Mahajan, Srushti ; Singh, Hoshiyar ; Guru, Santosh Kumar ; Singh, Pankaj Kumar
  • Assuntos: Biomedical and Life Sciences ; Biomedicine ; Breast Neoplasms - drug therapy ; Female ; Humans ; Nanomedicine ; Pharmaceutical Sciences/Technology ; Receptors, Estrogen - metabolism ; Receptors, Estrogen - therapeutic use ; Review Article
  • É parte de: Drug delivery and translational research, 2023-06, Vol.13 (6), p.1621-1653
  • Descrição: Breast cancer (BC) is the most frequently diagnosed malignancy in women worldwide. Almost 70–80% of cases of BC are curable at the early non-metastatic stage. BC is a heterogeneous disease with different molecular subtypes. Around 70% of breast tumors exhibit estrogen-receptor (ER) expression and endocrine therapy is used for the treatment of these patients. However, there are high chances of recurrence in the endocrine therapy regimen. Though chemotherapy and radiation therapy have substantially improved survival rates and treatment outcomes in BC patients, there is an increased possibility of the development of resistance and dose-limiting toxicities. Conventional treatment approaches often suffer from low bioavailability, adverse effects due to the non-specific action of chemotherapeutics, and low antitumor efficacy. Nanomedicine has emerged as a conspicuous strategy for delivering anticancer therapeutics in BC management. It has revolutionized the area of cancer therapy by increasing the bioavailability of the therapeutics and improving their anticancer efficacy with reduced toxicities on healthy tissues. In this article, we have highlighted various mechanisms and pathways involved in the progression of ER-positive BC. Further, different nanocarriers delivering drugs, genes, and natural therapeutic agents for surmounting BC are the spotlights of this article. Graphical Abstract
  • Editor: New York: Springer US
  • Idioma: Inglês
Links
Voltar para lista de resultados
Resultado  1 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.